Evaluate Prediabetic, Diabetic, and Late-Stage Diabetic Complications in One Translational Platform
Evaluate Efficacy for T1D or T2D
Diabetes is a chronic, progressive, incurable disease which has now reached global epidemic proportions. 90% of diabetic patients present the Type 2 form (T2D) which manifests as persistent hyperglycemia and is mainly linked to excess body weight, unhealthy diet, inactivity, and aging.
Type 1 (T1D) is the often overlooked form of diabetes due to still unknown factors. The underlying pathological mechanism involves autoimmune destruction of the insulin-producing beta cells in the pancreas.
Current antidiabetic therapies have significant side effects; therefore new agents are required with fewer risks, and to control diabetic complications. At the same time, appropriate technologies and models are needed to enhance preclinical evaluation of novel agents, before they reach human patients.
Reduced Glucose Disposition in Spontaneously Diabetic NHPs by Hyperglycemia Clamp Analysis
A Unique Platform of Highly Translatable Rodent and NHP models
CrownBio’s preclinical CardioVascular and Metabolic Disease (CVMD) Translational Technology Platforms help support the transition of new antidiabetic agents from lead compounds into the clinic. We provide rodent and NHP models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models, in studies with key endpoints for in vivo efficacy evaluation of antidiabetic agents.
Spontaneous and Diet-induced NHP Models
NHP models are by far the most predictive animal model system for human metabolic syndrome including diabetes, presenting complex symptoms such as loss of blood glucose control, dyslipidemia, and diabetic complications. This is especially critical since many next generation drugs for metabolic disease target diabetic complications rather than blood glucose control. Evaluating drugs in such models offers tremendous value towards understanding efficacy, PK/PD relationship, biomarkers, and possible adverse effects.
CrownBio provides the world’s largest collection of spontaneously diabetic NHPs that mirror all aspects of human diabetes progression including late stage disease complications. In addition to our spontaneously diabetic NHPs at CrownBio, we have also established NHP models of diet-induced T2D.
Insulin Resistance Observed in Spontaneously Diabetic NHPs by Euglycemia Clamp Analysis
Unique Rodent Models with Intact Leptin Pathway Mimic All Stages of Human Disease
Our rodent models of diabetes include conventional models for comparison with historical data sets, including:
- STZ-induced T1D diabetic models
- Spontaneous T1D models (NOD and NRG-Akita mice, BB rat)
- ZDF, ZSF-1 rat models of T2D
- db/db and ob/ob mouse models of T2D
As well as translational polygenic models that more closely reflect the human condition:
A Comprehensive Platform of Analytical Services
Available study endpoints at CrownBio for in vivo efficacy evaluation of antidiabetic agents include:
- Insulin measurement (Chemiluminescence, MesoScale Discovery)
- Glucose measurement (NovaBiomedical Stat Strip® Xpress in rodents)
- Continuous glucose monitoring (DSI telemetry technology in NHPs and rodents)
- Glucose intolerance and impaired insulin response (GTT or oGTT)
- Insulin resistance (ITT)
- Glucose disposition/insulin resistance (clamps)
Contact us today to discuss your diabetes project needs and experience the value of our expert translational service.